Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05507151
Other study ID # 2202523300
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 24, 2022
Est. completion date May 2024

Study information

Verified date April 2023
Source West Virginia University
Contact Shailendra Singh, MD
Phone 304-293-4123
Email shailendra.singh@hsc.wvu.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Endoscopic weight loss procedures, also termed endoscopic sleeve gastroplasty (ESG), has been proposed as a non-surgical procedure for managing obesity and offers a standard weight loss approach. Realizing there is a knowledge gap in applying ESG to morbidly obese patients with NAFLD, the investigators propose studying the efficacy of weight control and functional outcomes of ESG. This prospective pilot study is aimed to study the safety profiles, quality of life, and changes and improvements in the anthropometric, metabolic, and biochemical changes in these patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date May 2024
Est. primary completion date May 2024
Accepts healthy volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Body mass index (BMI) greater than 30 kg/m2, who are eligible for ESG - Patients scheduled to undergo an endoscopic bariatric weight loss procedure (ESG) - Patients older than 18 years and younger than 75 years of age at the time of consent - Patients able to provide written informed consent on the Institutional review board (IRB) approved informed consent form - Patients willing and able to comply with study requirements for follow-up Exclusion criteria: - Patients who are treated with intragastric balloons - Family history of esophageal, gastric, or duodenal malignancy and active gastric ulceration, - Pre-existing esophageal stenosis/stricture preventing the advancement of an endoscope during screening/baseline Esophagogastroduodenoscopy (EGD) - Presence of any gastric condition which required endoscopic surveillance (e.g., known gastric intestinal metaplasia), - Known vascular abnormalities, obligate therapeutic anticoagulation, and pregnancy/lactation - Evidence of end-stage liver disease, including portal hypertension, ascites, and coagulopathy - Positivity for hepatitis B virus or hepatitis C virus, current alcohol consumption of more than 20 g/day in females and more than 30 g/day in males on average, use of medications with reported hepato-steatogenic effect (amiodarone, tamoxifen, estrogens), and drug-induced liver disease - Type 1 diabetes, Prior bariatric surgery, Autoimmune liver disease (antinuclear antibody titer >1/160), Wilson's disease, hemochromatosis, alpha1-antitrypsin deficiency, - Known positivity for human immunodeficiency virus, a concomitant disease with reduced life expectancy, severe psychiatric condition, drug dependence, or inability to provide informed consent. - The patient refuses or is unable to provide written informed consent - Prior bariatric treatment procedure

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Endoscopic Sleeve Gastroplasty
endoscopic suturing of the stomach

Locations

Country Name City State
United States West Virginia University Morgantown West Virginia

Sponsors (1)

Lead Sponsor Collaborator
West Virginia University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Controlled Attenuation Parameter of Steatosis The CAP measures ultrasonic attenuation in the liver at 3.5 MHz using signals acquired by the FibroScan® M probe based on vibration-controlled transient elastography. The final CAP value, which ranges from 100 to 400 decibels per metre (dB/m), is the median of individual measurements. Higher measure indicates higher portion of liver affected by fatty change. Baseline (Before ESG)
Primary Change in Controlled Attenuation Parameter of Steatosis The CAP measures ultrasonic attenuation in the liver at 3.5 MHz using signals acquired by the FibroScan® M probe based on vibration-controlled transient elastography. The final CAP value, which ranges from 100 to 400 decibels per metre (dB/m), is the median of individual measurements. Higher measure indicates higher portion of liver affected by fatty change. 6 months post ESG
Primary Change in Controlled Attenuation Parameter of Steatosis The CAP measures ultrasonic attenuation in the liver at 3.5 MHz using signals acquired by the FibroScan® M probe based on vibration-controlled transient elastography. The final CAP value, which ranges from 100 to 400 decibels per metre (dB/m), is the median of individual measurements. Higher measure indicates higher portion of liver affected by fatty change. 12 months post ESG
Primary Change in Liver Stiffness Measurement of Fibrosis Liver stiffness result is measured in kilopascals (kPa) Range is 0-75kPa. Normal results are usually between 2 and 7 kPa. The highest possible result is 75 kPa. Higher results indicate liver disease. Baseline (Before ESG)
Primary Change in Liver Stiffness Measurement of Fibrosis Liver stiffness result is measured in kilopascals (kPa) Range is 0-75kPa. Normal results are usually between 2 and 7 kPa. The highest possible result is 75 kPa. Higher results indicate liver disease. 6 months post ESG
Primary Change in Liver Stiffness Measurement of Fibrosis Liver stiffness result is measured in kilopascals (kPa) Range is 0-75kPa. Normal results are usually between 2 and 7 kPa. The highest possible result is 75 kPa. Higher results indicate liver disease. 12 months post ESG
Secondary Anthropometric Evaluation Changes in Anthropometric evaluation from baseline to 6 months post ESG 6 months post ESG
Secondary BMI Changes Compare the change in BMI from baseline to the 6 months post ESG. Body Mass Index (BMI) is a person's weight in kilograms (or pounds) divided by the square of height in meters (or feet). 6 months post ESG
Secondary BMI Changes Compare the change in BMI from baseline to the 12 months post ESG. Body Mass Index (BMI) is a person's weight in kilograms (or pounds) divided by the square of height in meters (or feet). 12 months post ESG
Secondary Excess Weight Loss Changes Percent excess weight loss change from baseline to 6 months 6 months post ESG
Secondary Excess Weight Loss Changes Percentage of excess weight loss change from baseline to 12 months 12 months post ESG
Secondary Total Body Weight Loss Changes Percentage of total body weight loss (TBWL) from baseline to 6 months 6 months post ESG
Secondary Total Body Weight Loss Changes Percentage of total body weight loss (TBWL) from baseline to 12 months 12 months post ESG
Secondary Absolute Body Weight Loss Changes Percentage of Absolute Body Weight Loss from baseline to 6 months 6 months post ESG
Secondary Absolute Body Weight Loss Changes Percentage of Absolute Body Weight Loss from baseline to 12 months 12 months post ESG
See also
  Status Clinical Trial Phase
Withdrawn NCT06138327 - A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria Phase 1
Completed NCT01045499 - LAGB as a Treatment for Morbid Obesity in Adolescents N/A
Completed NCT03674476 - An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function Phase 1
Not yet recruiting NCT05495139 - Gastric Bypass Stent Small-Sample-Size Study For Nonalcoholic Fatty Liver Disease N/A
Completed NCT04988204 - Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease N/A
Recruiting NCT04369521 - Evaluation of the Effects of a Low Free Sugar Diet in Patients With Nonalcoholic Fatty Liver Disease N/A
Completed NCT01934777 - Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis Phase 3
Enrolling by invitation NCT00983463 - Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)
Recruiting NCT00658164 - Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores Phase 3
Recruiting NCT02148471 - Fatty Acids, Genes and Microbiota in Fatty Liver N/A
Completed NCT06441409 - Serum Ferritin Levels and Metabolic Dysfunction Associated Steatotic Liver Disease N/A
Completed NCT03656744 - A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) Phase 2
Not yet recruiting NCT01735799 - THE ASSOCIATION BETWEEN FATTY LIVER (NAFLD) DISEASE AND PCOS N/A
Completed NCT01446276 - Long-term Investigation of Resveratrol on Fat Metabolism in Obese Men With Nonalcoholic Fatty Liver Disease N/A
Completed NCT00930384 - A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis N/A
Recruiting NCT02469272 - Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study Phase 1
Completed NCT02132780 - Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease N/A
Completed NCT01399645 - Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes Phase 2
Terminated NCT01355575 - Rifaximin in Fatty Liver Disease Phase 4
Completed NCT01210989 - Trial of Hepaguard® in Adults With Nonalcoholic Steatohepatitis N/A